查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049328

囊腫纖維化治療市場報告：按藥物類別、分子類型、給藥途徑、最終用戶和地區分類（2026-2034 年）

Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球囊腫纖維化治療市場規模達84億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到160億美元，2026年至2034年的複合年成長率為7.25% 。囊腫纖維化盛行率的上升、個人對基於基因因素的個人化治療方案的日益青睞，以及基因療法最新進展的廣泛應用，是推動市場成長的主要因素。

囊腫纖維化藥物能夠有效控制這種影響呼吸系統和消化器官系統的遺傳性疾病的症狀。這些藥物種類繁多，包括CFTR調變器和基因療法，可提供個人化的治療方案。這些藥物透過增強CFTR蛋白的功能，幫助糾正導致囊腫纖維化的潛在基因缺陷。它們透過控制症狀和延緩疾病進展，有助於提高患者的生活品質。此外，它們還能改善肺功能，使患者呼吸更順暢，並減輕囊腫纖維化症狀。

公眾對基於基因因素的個人化醫療日益成長的興趣正在推動市場成長。此外，各國監管機構正在實施相關政策並為囊性纖維化（CF）的研發提供資金支持，這為市場前景創造了有利條件。同時，不斷增加的孤兒藥研發監管獎勵也鼓勵製藥公司投資CF治療。製藥公司、研究機構和醫療服務提供者之間合作的加強也加速了新治療方法的研發。此外，穿戴式裝置和遠端醫療等技術的廣泛應用正在改善患者監測和治療方案的實施。

囊腫纖維化治療市場的趨勢與促進因素：

CFTR調變器的研究進展

CFTR調變器藥物的研發和持續改善是市場成長的關鍵驅動力。這些藥物直接針對導致囊性纖維化患者黏液過度分泌及相關健康併發症的缺陷CFTR蛋白。此外，藥廠不斷增加研發投入，致力於推出療效更高、適用範圍更廣的新一代CFTR調變器。這些進展提供了更全面的解決方案，改善了患者的整體健康。它們還有助於增加粘液排放，減輕呼吸道症狀，並改善某些囊腫纖維化患者的肺功能。

基因治療的發展

基因治療方法的發展是推動市場成長的另一個主要因素。這些創新治療方法透過將功能正常的CFTR基因拷貝導入受影響的細胞，從根本上解決囊性纖維化（CF）的病因，從而實現治癒或長期控制CF。此外，基因療法領域的最新進展，例如Kaftrio和Trikafta等基因療法核准用於治療CF症狀，也為市場帶來了良好的前景。基因療法的不斷發展也在促進市場成長。這些治療方法有助於提供更有效、更具針對性的治療方案，拓展治療選擇，並推動對潛在根治性方法的研究。

盛行率增加和早期診斷

多種因素正在推動對治療的需求，尤其是千禧世代中囊性纖維化（CF）盛行率的不斷上升。此外，診斷能力的提升也提振了市場前景。同時，醫療系統正透過新生兒篩檢計畫和基因檢測來提高CF病例的識別能力。早期診斷使得患者能夠在較小的年齡開始治療，從而顯著影響疾病進展並改善長期預後。此外，基因檢測和新生兒篩檢計畫的持續進步使得嬰兒CF的診斷更加快速可靠。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：囊腫纖維化治療藥物的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類別分類

  • 亞酵素補充劑
  • 祛痰藥
  • 支氣管擴張劑
  • CFTR調變器
  • 抗生素
  • 其他

第7章 市場區隔：依藥物分子類型分類

  • 小分子藥物
  • 生物製劑

第8章 市場區隔：依給藥途徑

  • 口服藥物
  • 吸入藥物

第9章 市場區隔：依最終用戶分類

  • 醫院
  • 診所
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbvie Inc.
    • Alaxia
    • Alcresta Therapeutics Inc.
    • Allergan
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Vertex Pharmaceuticals Inc.
Product Code: SR112026A2117

The global cystic fibrosis therapeutics market size reached USD 8.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 16.0 Billion by 2034, exhibiting a growth rate (CAGR) of 7.25% during 2026-2034. The rising prevalence of cystic fibrosis, increasing preferences of individuals for personalized treatment approaches based on genetic factors, and the widespread utilization of recent advancements in gene therapy are some of the major factors propelling the market growth.

Cystic fibrosis therapeutics enables management of the symptoms of a genetic disease affecting the respiratory and digestive systems. It encompasses a range of drugs, including CFTR modulators and gene therapy, offering tailored treatment options. It helps correct the underlying genetic defect responsible for CF by enhancing the function of the CFTR protein. It contributes to a better quality of life by managing symptoms and slowing disease progression. It can enhance lung function, helping individuals with CF breathe more easily and reducing respiratory symptoms.

Rising preferences of individuals for personalized treatment approaches based on genetic factors is strengthening the growth of the market. Apart from this, governing authorities of various countries are introducing policies and funding for CF research and treatment development, which is offering a favorable market outlook. Additionally, a continuous rise in regulatory incentives for orphan drug development is encouraging pharmaceutical companies to invest in CF therapeutics. Moreover, the rising collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development of new therapies. Furthermore, the widespread use of technology, such as wearable devices and telemedicine, is enhancing patient monitoring and treatment delivery.

CYSTIC FIBROSIS THERAPEUTICS MARKET TRENDS/DRIVERS:

Advancements in CFTR modulators

The development and continued improvement of CFTR modulator drugs represent one of the primary factors contributing to the market growth. These medications directly target the defective CFTR protein, which is responsible for the thick mucus production and subsequent health complications in individuals with CF. Apart from this, pharmaceutical companies are continuously investing in research and development (R&D) activities to introduce new generations of CFTR modulators that offer greater effectiveness and broader applicability. These advancements provide more comprehensive solutions and improve the overall well-being of individuals. They also support improved mucus clearance, reduced respiratory symptoms, and enhanced lung function in specific CF patient populations.

Development of gene-based therapies

The development of gene-based therapies is another major factor facilitating the market growth. These innovative treatments help address the root cause of CF by introducing functional copies of the defective CFTR gene into affected cells and facilitating a cure or long-term management of CF. Additionally, the rising utilization of recent advancements in gene therapy, such as the approval of gene-based treatments like Kaftrio and Trikafta for treating CF symptoms is offering a favorable market outlook. Apart from this, the evolution of gene-based therapies is strengthening the growth of the market. These therapies aid in providing more effective and targeted treatments, expanding treatment options, and fostering research into potential curative approaches.

Increasing prevalence and early diagnosis

The rising prevalence of CF, especially among the millennial population due to several factors, is driving the demand for therapeutics. Along with this, improved diagnostic capabilities are creating a positive market outlook. Additionally, healthcare systems are becoming more adept at identifying CF cases through newborn screening programs and genetic testing. Apart from this, early diagnosis allows for the initiation of treatment at a younger age, which can significantly impact disease progression and improve long-term outcomes. Furthermore, ongoing advancements in genetic testing and newborn screening programs are allowing for quicker and more reliable diagnosis of CF in infants and young children.

CYSTIC FIBROSIS THERAPEUTICS INDUSTRY SEGMENTATION:

Breakup by Drug Class:

  • Pancreatic Enzyme Supplements
  • Mucolytics
  • Bronchodilators
  • CFTR Modulators
  • Antibiotics
  • Others

CFTR modulators hold the largest market share

Breakup by Drug Molecule Type:

  • Small Molecule Drugs
  • Biologics

Small molecule drugs account for the majority of the market share

Breakup by Route of Administration:

  • Oral Drugs
  • Inhaled Drugs

Oral drugs dominate the market

Breakup by End-User:

  • Hospitals
  • Clinics
  • Others

Hospitals dominate the market

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Europe leads the market, accounting for the largest cystic fibrosis therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share since the region has a well-developed healthcare infrastructure with widespread access to medical facilities and specialized CF centers. Additionally, Europe has a relatively high prevalence of CF. This increased prevalence drives research and development (R&D) efforts as well as market demand for CF therapeutics. Apart from this, Europe is home to some of the largest pharmaceutical companies in the world. These companies invest heavily in CF therapeutics, leading to the development of innovative treatments. Furthermore, the European Medicines Agency (EMA) provides a clear regulatory pathway for the approval of CF drugs. Moreover, many European governments allocate substantial funding to support CF research and treatment. This funding accelerates the development of new therapies and promotes market growth.

COMPETITIVE LANDSCAPE:

Companies are investing heavily in research and development (R&D) activities to discover new treatments and medications that target the underlying causes of cystic fibrosis. Additionally, they are working on therapies tailored to specific genetic mutations associated with cystic fibrosis. This ensures a more effective and targeted approach to treatment. Apart from this, many companies are forming partnerships with academic institutions, research organizations, and other pharma companies to accelerate drug development and bring new therapies to market more quickly. Furthermore, they are continuously conducting and investing in phase I, II, and III clinical trials to test the efficacy and safety of new cystic fibrosis therapies.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • Alaxia
  • Alcresta Therapeutics Inc.
  • Allergan
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global cystic fibrosis therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global cystic fibrosis therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global cystic fibrosis therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug class?
  • Which is the most attractive drug class in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the drug molecule type?
  • Which is the most attractive drug molecule type in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the route of administration?
  • Which is the most attractive route of administration in the cystic fibrosis therapeutics market?
  • What is the breakup of the market based on the end-user?
  • Which is the most attractive end-user in the cystic fibrosis therapeutics market?
  • What is the competitive structure of the global cystic fibrosis therapeutics market?
  • Who are the key players/companies in the global cystic fibrosis therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cystic Fibrosis Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Pancreatic Enzyme Supplements
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mucolytics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Bronchodilators
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 CFTR Modulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Molecule Type

  • 7.1 Small Molecule Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Inhaled Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alaxia
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Alcresta Therapeutics Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Allergan
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 AstraZeneca
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 F. Hoffmann-La Roche Ltd
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Gilead Sciences Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novartis AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Vertex Pharmaceuticals Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cystic Fibrosis Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Cystic Fibrosis Therapeutics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Cystic Fibrosis Therapeutics Market: Breakup by Drug Molecule Type (in %), 2025
  • Figure 5: Global: Cystic Fibrosis Therapeutics Market: Breakup by Route of Administration (in %), 2025
  • Figure 6: Global: Cystic Fibrosis Therapeutics Market: Breakup by End-User (in %), 2025
  • Figure 7: Global: Cystic Fibrosis Therapeutics Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Cystic Fibrosis Therapeutics (Pancreatic Enzyme Supplements) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Cystic Fibrosis Therapeutics (Mucolytics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Cystic Fibrosis Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Cystic Fibrosis Therapeutics (CFTR Modulators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Cystic Fibrosis Therapeutics (Antibiotics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Cystic Fibrosis Therapeutics (Small Molecule Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Cystic Fibrosis Therapeutics (Biologics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Cystic Fibrosis Therapeutics (Biologics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Cystic Fibrosis Therapeutics (Oral Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Cystic Fibrosis Therapeutics (Inhaled Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Cystic Fibrosis Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Cystic Fibrosis Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Cystic Fibrosis Therapeutics (Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Cystic Fibrosis Therapeutics (Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Cystic Fibrosis Therapeutics (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Cystic Fibrosis Therapeutics (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: North America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: North America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: United States: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: United States: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Canada: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Canada: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Asia Pacific: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Asia Pacific: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: China: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: China: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Japan: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Japan: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: India: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: India: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: South Korea: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: South Korea: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Australia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Australia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Indonesia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Indonesia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Europe: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Europe: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Germany: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Germany: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: France: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: France: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: United Kingdom: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: United Kingdom: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Italy: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Italy: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Spain: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Spain: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Russia: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Russia: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Latin America: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Latin America: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Brazil: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Brazil: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Mexico: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Mexico: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Others: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Others: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Middle East and Africa: Cystic Fibrosis Therapeutics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Middle East and Africa: Cystic Fibrosis Therapeutics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Global: Cystic Fibrosis Therapeutics Industry: SWOT Analysis
  • Figure 84: Global: Cystic Fibrosis Therapeutics Industry: Value Chain Analysis
  • Figure 85: Global: Cystic Fibrosis Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cystic Fibrosis Therapeutics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Drug Molecule Type (in Million USD), 2026-2034
  • Table 4: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 5: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by End-User (in Million USD), 2026-2034
  • Table 6: Global: Cystic Fibrosis Therapeutics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Cystic Fibrosis Therapeutics Market Structure
  • Table 8: Global: Cystic Fibrosis Therapeutics Market: Key Players